Sökning: onr:"swepub:oai:DiVA.org:uu-494356" >
Macrophage Activati...
Macrophage Activation Marker Neopterin : A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
2018-06-01
-
Frontiers Media SA,2018
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-494356
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-494356URI
-
https://doi.org/10.3389/fcimb.2018.00181DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
The Leishmania parasite resides and replicates within host macrophages during visceral leishmaniasis (VL). This study aimed to evaluate neopterin, a marker of macrophage activation, as possible pharmacodynamic biomarker to monitor VL treatment response and to predict long-term clinical relapse of VL. Following informed consent, 497 plasma samples were collected from East-African VL patients receiving a 28-day miltefosine monotherapy (48 patients) or 11-day combination therapy of miltefosine and liposomal amphotericin B (L-AMB, 48 patients). Neopterin was quantified with ELISA. Values are reported as median (inter-quartile range). Baseline neopterin concentrations were elevated in all VL patients at 98.8 (63.9-135) nmol/L compared to reported levels for healthy controls (<10 nmol/L). During the first treatment week, concentrations remained stable in monotherapy patients (p = 0.807), but decreased two-fold compared to baseline in the combination therapy patients (p < 0.01). In the combination therapy arm, neopterin concentrations increased significantly 1 day after L-AMB infusion compared to baseline for cured patients [137 (98.5-197) nmol/L, p < 0.01], but not for relapsing patients [84.4 (68.9-106) nmol/L, p = 0.96]. The neopterin parameter with the highest predictive power for VL relapse was a higher than 8% neopterin concentration increase between end of treatment and day 60 follow-up (ROC AUC 0.84), with a 93% sensitivity and 65% specificity. In conclusion, the identified neopterin parameter could be a potentially useful surrogate endpoint to identify patients in clinical trials at risk of relapse earlier during follow-up, possibly in a panel of biomarkers to increase its specificity.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Wasunna, Monique
(författare)
-
Alves, Fabiana
(författare)
-
Schellens, Jan H M
(författare)
-
Beijnen, Jos H
(författare)
-
Musa, Ahmed M
(författare)
-
Khalil, Eltahir A G
(författare)
-
Dorlo, Thomas P CNetherlands Cancer Institute(Swepub:uu)thodo249
(författare)
-
Netherlands Cancer Institute
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Frontiers in Cellular and Infection Microbiology: Frontiers Media SA8, s. 181-2235-2988
Internetlänk
Hitta via bibliotek
Till lärosätets databas